LIVE
Saving a Water-Damaged Smartphone: 4 Mistakes to Avoid EU spent more on Russian energy than on aid to Ukraine, European Commission data shows SpaceX hires Washington lobbyists ahead of potential US Congressional probes Geopolitical summit in China: expert assessment of the meeting between US, Chinese, and Russian leaders Strikes on the Crimean Bridge: Economic Impact on Logistics and Shipping EU to Provide €1 Billion for Military Equipment for Ukraine Technological Superiority and the Crimean Bridge: Expert Analysis Zelenskyy Reaffirms Legitimacy of Strikes on Crimean Bridge Russian strike destroys Fresh Production Group's film studio Energy infrastructure in Rivne region damaged by attack: 50 settlements left without power Saving a Water-Damaged Smartphone: 4 Mistakes to Avoid EU spent more on Russian energy than on aid to Ukraine, European Commission data shows SpaceX hires Washington lobbyists ahead of potential US Congressional probes Geopolitical summit in China: expert assessment of the meeting between US, Chinese, and Russian leaders Strikes on the Crimean Bridge: Economic Impact on Logistics and Shipping EU to Provide €1 Billion for Military Equipment for Ukraine Technological Superiority and the Crimean Bridge: Expert Analysis Zelenskyy Reaffirms Legitimacy of Strikes on Crimean Bridge Russian strike destroys Fresh Production Group's film studio Energy infrastructure in Rivne region damaged by attack: 50 settlements left without power

FDA mandates label updates for popular weight-loss drugs over potential vision risks

🏢 Бізнес 1 min read 👁 4

The US FDA is requiring updates to warnings for GLP-1 receptor agonists due to a potential link to a rare eye condition.

FDA mandates label updates for popular weight-loss drugs over potential vision risks🏢Бізнес

Photo: rbc.ua

Key points

  • FDA mandates label warnings for GLP-1 class drugs
  • Potential risk of NAION vision condition identified
  • Patients advised to seek medical help if symptoms appear

The U.S. Food and Drug Administration (FDA) has requested that manufacturers of diabetes and weight-loss medications, including Ozempic, Wegovy, Mounjaro, and Zepbound, update their product labels. The move follows concerns regarding a potential link between these GLP-1 medications and non-arteritic anterior ischemic optic neuropathy (NAION).

Understanding the medical risk

NAION is a rare condition involving compromised blood flow to the optic nerve, which can lead to sudden and often permanent vision loss. An analysis of 126 clinical studies involving over 134,000 participants indicated a higher incidence of this condition among users of GLP-1 drugs compared to those who received a placebo or other treatments.

The regulator clarifies that a definitive causal relationship has not yet been established. Nevertheless, patients are advised to monitor for symptoms such as sudden vision impairment, blurred vision, or color perception changes. It is crucial to seek immediate medical attention if these symptoms occur, rather than discontinuing the medication without professional guidance.

Source rbc.ua — wave.rbc.ua/ukr/wellness/populyarni-preparati-shudnennya-pov-yazali-179… ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.